Néovacs Secures €2M from France 2030 for its mRNA Vectors
Néovacs has been selected as a partner in the VECT-PI project to receive funding of €2M over 42 months under the France 2030 program. The project, led by CNRS and scientifically coordinated by Dr. Nathalie Mignet, aims to develop innovative lipids for mRNA vectors.
Selection in a Highly Competitive Process
The VECT-PI project was officially selected by the National Research Agency (ANR) as part of the 2025 call for projects under the 'Biotherapies and Bioproduction of Innovative Therapies' (PEPR BBTI) research program. Out of 13 eligible projects, 7 were reviewed by an international committee of experts before only the most innovative and structuring projects were chosen.
The Role of Néovacs and Project Objectives
Néovacs plays a role in the consortium as the leader of therapeutic applications. The VECT-PI project aims to develop new innovative lipids for the formulation of lipid nanoparticles (LNPs) of mRNA supervised by artificial intelligence, with the goal of improving efficacy and tolerance. These LNPs will be produced by microfluidics and associated with modeling and automation tools. Two Work Packages are directly entrusted to Néovacs, focusing on psoriasis and colorectal cancer. This participation is part of Néovacs' strategy to strengthen its technological portfolio in next-generation biotherapies and to explore emerging therapeutic applications of LNPs.
